The once-weekly basal insulin therapy market size has grown rapidly in recent years. It will grow from $3.4 billion in 2025 to $3.87 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to predominance of once-daily basal insulin injection regimens, short duration of action of early insulin analog formulations, low adherence among patients to frequent injection schedules, complexity of conventional glucose monitoring systems, absence of once-weekly basal insulin therapy options.
The once-weekly basal insulin therapy market size is expected to see rapid growth in the next few years. It will grow to $6.51 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to a shift toward ultra-long-acting insulin innovations, rising demand for patient-centric diabetes management solutions, increasing growth of home-based and decentralized care models, advancements in sustained-release insulin technologies, and expansion of basal insulin intensification treatment pathways. Major trends in the forecast period include development of ultra-long-acting once-weekly basal insulin analogs, improved patient adherence driven by reduced injection frequency therapies, expansion of prefilled pen and auto-injector insulin delivery systems, clinical emphasis on lowering hypoglycemia risk and enhancing glycemic stability, and increasing adoption of homecare-based diabetes management solutions.
The rising global diabetes prevalence is expected to propel the growth of the once-weekly basal insulin therapy market going forward. Diabetes prevalence refers to the increasing number of individuals diagnosed with diabetes within a population over a specific period. The global diabetes prevalence is increasing due to rising obesity levels and aging populations, which continue to increase diabetes incidence worldwide. Once-weekly basal insulin therapy helps in the management of diabetes mellitus by providing long-acting blood glucose control with fewer injections, improving treatment adherence, and patient convenience. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based diabetes organization, 589 million adults aged 20-79 years were living with diabetes globally in 2024, and the total number is projected to increase to 853 million by 2050. Therefore, the rising global diabetes prevalence is driving the growth of the once-weekly basal insulin therapy market.
The increasing prevalence of obesity is expected to propel the growth of the once-weekly basal insulin therapy market going forward. Obesity refers to a chronic medical condition characterized by excessive body fat accumulation that increases the risk of metabolic and cardiovascular diseases, including diabetes. The increasing prevalence of obesity is rising due to unhealthy dietary habits, sedentary lifestyles, and reduced physical activity levels worldwide. Once-weekly basal insulin therapy is used in the management of diabetes mellitus to provide long-acting blood glucose control with fewer injections, improving treatment adherence and patient convenience. For instance, in March 2024, according to the World Obesity Federation, a UK-based organization focused on obesity prevention, treatment, and policy advocacy, the number of adults living with obesity is projected to increase from 1.01 billion in 2025 to 1.53 billion by 2035. Therefore, the increasing prevalence of obesity is driving the growth of the once-weekly basal insulin therapy market.
Leading companies operating in the once-weekly basal insulin therapy market are focusing on developing advanced long-acting insulin formulations to reduce injection frequency, improve treatment adherence, and enhance patient convenience in diabetes management. Long-acting insulin formulations are insulin therapies designed to provide a steady and prolonged release of insulin to maintain stable blood glucose levels while reducing blood sugar fluctuations and the need for frequent injections. For example, in March 2026, Novo Nordisk, a Denmark-based pharmaceutical company, received U.S. FDA approval for Awiqli (insulin icodec), the first once-weekly basal insulin treatment for adults with type 2 diabetes. The therapy is designed to reduce injection frequency while supporting improved patient convenience and long-term diabetes management, aligning with the growing adoption of digitally enabled diabetes care solutions.
Major companies operating in the once-weekly basal insulin therapy market are Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Gan & Lee Pharmaceuticals,Tonghua Dongbao Pharmaceutical Co. Ltd.,Gerresheimer AG,Ypsomed Holding AG.
North America was the dominant region in the once-weekly basil insulin therapy market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in once-weekly basal insulin therapy report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the once-weekly basal insulin therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The once-weekly basal insulin therapy market consists of sales of long-acting weekly insulin formulations, diabetes management therapies, ultra-long-acting insulin analogs, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The once-weekly basal insulin therapy market research report is one of a series of new reports that provides once-weekly basal insulin therapy market statistics, including once-weekly basal insulin therapy industry global market size, regional shares, competitors with a once-weekly basal insulin therapy market share, detailed once-weekly basal insulin therapy market segments, market trends and opportunities, and any further data you may need to thrive in the once-weekly basal insulin therapy industry. This once-weekly basal insulin therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The once-weekly basal insulin therapy market size is expected to see rapid growth in the next few years. It will grow to $6.51 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to a shift toward ultra-long-acting insulin innovations, rising demand for patient-centric diabetes management solutions, increasing growth of home-based and decentralized care models, advancements in sustained-release insulin technologies, and expansion of basal insulin intensification treatment pathways. Major trends in the forecast period include development of ultra-long-acting once-weekly basal insulin analogs, improved patient adherence driven by reduced injection frequency therapies, expansion of prefilled pen and auto-injector insulin delivery systems, clinical emphasis on lowering hypoglycemia risk and enhancing glycemic stability, and increasing adoption of homecare-based diabetes management solutions.
The rising global diabetes prevalence is expected to propel the growth of the once-weekly basal insulin therapy market going forward. Diabetes prevalence refers to the increasing number of individuals diagnosed with diabetes within a population over a specific period. The global diabetes prevalence is increasing due to rising obesity levels and aging populations, which continue to increase diabetes incidence worldwide. Once-weekly basal insulin therapy helps in the management of diabetes mellitus by providing long-acting blood glucose control with fewer injections, improving treatment adherence, and patient convenience. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based diabetes organization, 589 million adults aged 20-79 years were living with diabetes globally in 2024, and the total number is projected to increase to 853 million by 2050. Therefore, the rising global diabetes prevalence is driving the growth of the once-weekly basal insulin therapy market.
The increasing prevalence of obesity is expected to propel the growth of the once-weekly basal insulin therapy market going forward. Obesity refers to a chronic medical condition characterized by excessive body fat accumulation that increases the risk of metabolic and cardiovascular diseases, including diabetes. The increasing prevalence of obesity is rising due to unhealthy dietary habits, sedentary lifestyles, and reduced physical activity levels worldwide. Once-weekly basal insulin therapy is used in the management of diabetes mellitus to provide long-acting blood glucose control with fewer injections, improving treatment adherence and patient convenience. For instance, in March 2024, according to the World Obesity Federation, a UK-based organization focused on obesity prevention, treatment, and policy advocacy, the number of adults living with obesity is projected to increase from 1.01 billion in 2025 to 1.53 billion by 2035. Therefore, the increasing prevalence of obesity is driving the growth of the once-weekly basal insulin therapy market.
Leading companies operating in the once-weekly basal insulin therapy market are focusing on developing advanced long-acting insulin formulations to reduce injection frequency, improve treatment adherence, and enhance patient convenience in diabetes management. Long-acting insulin formulations are insulin therapies designed to provide a steady and prolonged release of insulin to maintain stable blood glucose levels while reducing blood sugar fluctuations and the need for frequent injections. For example, in March 2026, Novo Nordisk, a Denmark-based pharmaceutical company, received U.S. FDA approval for Awiqli (insulin icodec), the first once-weekly basal insulin treatment for adults with type 2 diabetes. The therapy is designed to reduce injection frequency while supporting improved patient convenience and long-term diabetes management, aligning with the growing adoption of digitally enabled diabetes care solutions.
Major companies operating in the once-weekly basal insulin therapy market are Eli Lilly and Company, Novo Nordisk A/S, Sanofi, Biocon, Gan & Lee Pharmaceuticals,Tonghua Dongbao Pharmaceutical Co. Ltd.,Gerresheimer AG,Ypsomed Holding AG.
North America was the dominant region in the once-weekly basil insulin therapy market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in once-weekly basal insulin therapy report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the once-weekly basal insulin therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The once-weekly basal insulin therapy market consists of sales of long-acting weekly insulin formulations, diabetes management therapies, ultra-long-acting insulin analogs, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The once-weekly basal insulin therapy market research report is one of a series of new reports that provides once-weekly basal insulin therapy market statistics, including once-weekly basal insulin therapy industry global market size, regional shares, competitors with a once-weekly basal insulin therapy market share, detailed once-weekly basal insulin therapy market segments, market trends and opportunities, and any further data you may need to thrive in the once-weekly basal insulin therapy industry. This once-weekly basal insulin therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Once-Weekly Basal Insulin Therapy Market Characteristics
3. Once-Weekly Basal Insulin Therapy Market Supply Chain Analysis
4. Global Once-Weekly Basal Insulin Therapy Market Trends And Strategies
5. Once-Weekly Basal Insulin Therapy Market Analysis Of End Use Industries
7. Global Once-Weekly Basal Insulin Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Once-Weekly Basal Insulin Therapy Total Addressable Market (TAM) Analysis for the Market
9. Once-Weekly Basal Insulin Therapy Market Segmentation
10. Once-Weekly Basal Insulin Therapy Market Regional And Country Analysis
11. Asia-Pacific Once-Weekly Basal Insulin Therapy Market
12. China Once-Weekly Basal Insulin Therapy Market
13. India Once-Weekly Basal Insulin Therapy Market
14. Japan Once-Weekly Basal Insulin Therapy Market
15. Australia Once-Weekly Basal Insulin Therapy Market
16. Indonesia Once-Weekly Basal Insulin Therapy Market
17. South Korea Once-Weekly Basal Insulin Therapy Market
18. Taiwan Once-Weekly Basal Insulin Therapy Market
19. South East Asia Once-Weekly Basal Insulin Therapy Market
20. Western Europe Once-Weekly Basal Insulin Therapy Market
21. UK Once-Weekly Basal Insulin Therapy Market
22. Germany Once-Weekly Basal Insulin Therapy Market
23. France Once-Weekly Basal Insulin Therapy Market
24. Italy Once-Weekly Basal Insulin Therapy Market
25. Spain Once-Weekly Basal Insulin Therapy Market
26. Eastern Europe Once-Weekly Basal Insulin Therapy Market
27. Russia Once-Weekly Basal Insulin Therapy Market
28. North America Once-Weekly Basal Insulin Therapy Market
29. USA Once-Weekly Basal Insulin Therapy Market
30. Canada Once-Weekly Basal Insulin Therapy Market
31. South America Once-Weekly Basal Insulin Therapy Market
32. Brazil Once-Weekly Basal Insulin Therapy Market
33. Middle East Once-Weekly Basal Insulin Therapy Market
34. Africa Once-Weekly Basal Insulin Therapy Market
36. Once-Weekly Basal Insulin Therapy Market Competitive Landscape And Company Profiles
37. Once-Weekly Basal Insulin Therapy Market Other Major And Innovative Companies
41. Once-Weekly Basal Insulin Therapy Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Once-Weekly Basal Insulin Therapy Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses once-weekly basal insulin therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for once-weekly basal insulin therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The once-weekly basal insulin therapy market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Type: Biosimilar Weekly Insulin; Insulin Icodec Awiqli; Next Generation Ultra Long Acting Insulin2) By Indication: Insulin Naive Patients; Type Two Diabetes; Type One Diabetes; Patients Requiring Basal Insulin Intensification
3) By Age Group: Geriatric; Adults; Pediatric
4) By End User: Ambulatory Care Centers; Hospitals; Diabetes Care Clinics; Homecare Settings
Subsegments:
1) By Biosimilar Weekly Insulin: Reference Biologic Weekly Insulin; Interchangeable Weekly Insulin; Long Acting Biosimilar Insulin; Recombinant Biosimilar Insulin; Prefilled Pen Biosimilar Insulin2) By Insulin Icodec Awiqli: Prefilled Injection Pen; Basal Once Weekly Insulin; Extended Duration Insulin Therapy; Adult Diabetes Therapy; Subcutaneous Insulin Formulation
3) By Next Generation Ultra Long Acting Insulin: Ultra Long Duration Basal Insulin; Hepato Preferential Insulin; Glucose Responsive Insulin; Combination Basal Insulin Therapy; Smart Insulin Formulations
Companies Mentioned: Eli Lilly and Company; Novo Nordisk A/S; Sanofi; Biocon; Gan & Lee Pharmaceuticals;Tonghua Dongbao Pharmaceutical Co. Ltd.;Gerresheimer AG;Ypsomed Holding AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Eli Lilly and Company
- Novo Nordisk A/S
- Sanofi
- Biocon
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical Co. Ltd.
- Gerresheimer AG
- Ypsomed Holding AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.87 Billion |
| Forecasted Market Value ( USD | $ 6.51 Billion |
| Compound Annual Growth Rate | 13.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
